selami demirci - Genetic Mutations

Author Information

Selami Demirci is a distinguished researcher affiliated with the Department of Genetics and Bioengineering at the Faculty of Engineering and Architecture, Yeditepe University, located in Istanbul, Turkey. His work is primarily focused on the field of genetics, with a particular interest in bioengineering applications. Through his position at Yeditepe University, Selami Demirci has contributed significantly to advancing genetic research, particularly in areas related to sickle cell disease and fetal hemoglobin induction.

Research Contributions

Selami Demirci has made substantial contributions to the field of genetics, as evidenced by his extensive publication record. His research primarily revolves around innovative genetic editing techniques, especially those aimed at treating beta-hemoglobinopathies and sickle cell disease. He has explored the use of CRISPR-Cas9 technology, the delivery of Cas9 protein via non-integrating lentiviral vectors, and the preclinical evaluation of gene-edited CD34+ cells. Additionally, his work on the protective roles of Cytoglobin and Neuroglobin against inflammation and the effects of Boron-Based Gel on radiation dermatitis highlight his diverse research interests and commitment to improving human health.

Aliases

No alternative aliases have been provided for Selami Demirci. He is consistently identified by his full name in professional and academic circles.

Publication and Citation Metrics

Metric	Value
Citation Count	1397
H-index	22
Paper Count	89

Publications:

Protective role of Cytoglobin and Neuroglobin against the Lipopolysaccharide (LPS)-induced inflammation in Leydig cells ex vivo.

DOI: 10.1016/j.repbio.2021.100595

Year: 2022

The Preventive Effects of Boron-Based Gel on Radiation Dermatitis in Patients Being Treated for Breast Cancer: A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial

DOI: 10.1159/000520363

Year: 2022

Sustained fetal hemoglobin induction in vivo is achieved by BCL11A interference and coexpressed truncated erythropoietin receptor

DOI: 10.1126/scitranslmed.abb0411

Year: 2021

CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease

DOI: 10.1016/j.omtm.2021.09.010

Year: 2021

Combined +58 and +55 BCL11A enhancer Editing Yields Exceptional Efficiency, Specificity and HbF Induction in Human and NHP Preclinical Models

DOI: 10.1182/blood-2021-152634

Year: 2021

Cas9 protein delivery non-integrating lentiviral vectors for gene correction in sickle cell disease

DOI: 10.1016/j.omtm.2021.02.022

Year: 2021

Preclinical evaluation for engraftment of CD34+ cells gene-edited at the sickle cell disease locus in xenograft mouse and non-human primate models

DOI: 10.1016/j.xcrm.2021.100247

Year: 2021

Genome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies.

DOI: 10.1093/hmg/ddaa088

Year: 2020

Biallelic correction of sickle cell disease‐derived induced pluripotent stem cells (iPSCs) confirmed at the protein level through serum‐free iPS‐sac/erythroid differentiation

DOI: 10.1002/sctm.19-0216

Year: 2020

Hematopoietic stem cells from pluripotent stem cells: Clinical potential, challenges, and future perspectives

DOI: 10.1002/sctm.20-0247

Year: 2020

What are Current Research Trends in Genetic Mutations?

How Do Point Mutations Occur?

What are Neutral Mutations?

What is the Prognosis for Individuals with Cystic Fibrosis?

How Common are BRCA1 and BRCA2 Mutations?

What is the Prognosis for Individuals with the Delta F508 Mutation?

How Does it Differ from Autosomal Dominant Inheritance?

What is Oxford Nanopore Sequencing?

What Future Research is Needed?

What Causes Sickle Cell Disease?

Partnered Content Networks

Relevant Topics